These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 33318068)
1. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. Buse JB; Bode BW; Mertens A; Cho YM; Christiansen E; Hertz CL; Nielsen MA; Pieber TR; BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33318068 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB; Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520 [TBL] [Abstract][Full Text] [Related]
3. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M; JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Ji L; Agesen RM; Bain SC; Fu F; Gabery S; Geng J; Li Y; Lu Y; Luo B; Pang W; Tao Y; Diabetologia; 2024 Sep; 67(9):1800-1816. PubMed ID: 38985161 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Wang W; Bain SC; Bian F; Chen R; Gabery S; Huang S; Jensen TB; Luo B; Yuan G; Ning G; Diabetologia; 2024 Sep; 67(9):1783-1799. PubMed ID: 38985162 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Ji L; Dong X; Li Y; Li Y; Lim S; Liu M; Ning Z; Rasmussen S; Skjøth TV; Yuan G; Eliaschewitz FG Diabetes Obes Metab; 2021 Feb; 23(2):404-414. PubMed ID: 33074557 [TBL] [Abstract][Full Text] [Related]
8. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E; Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547 [TBL] [Abstract][Full Text] [Related]
10. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ; Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120 [TBL] [Abstract][Full Text] [Related]
12. Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies. Rosenstock J; Cariou B; Eliasson J; Frappin G; Kaltoft MS; Montanya E; Knop FK Diabetes Obes Metab; 2024 Feb; 26(2):532-539. PubMed ID: 37935463 [TBL] [Abstract][Full Text] [Related]
13. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653 [TBL] [Abstract][Full Text] [Related]
14. PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes. Saravanan P; Bell H; Braae UC; Collins E; Deinega A; Dhatariya K; Machell A; Trent A; Strzelecka A Adv Ther; 2024 Nov; 41(11):4266-4281. PubMed ID: 39316289 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514 [TBL] [Abstract][Full Text] [Related]
16. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y; Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Araki E; Terauchi Y; Watada H; Deenadayalan S; Christiansen E; Horio H; Kadowaki T Diabetes Obes Metab; 2021 Dec; 23(12):2785-2794. PubMed ID: 34472698 [TBL] [Abstract][Full Text] [Related]
18. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C; Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]